Drug Trial Radar · NCT04459325
Tigerase® Efficacy and Safety as Part of Complex Therapy in Patients With COVID-19
Last checked: Nov 20, 2026Latest source record: Oct 14, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
100
Actual
Start
Jun 1, 2020
Primary completion
Jul 20, 2020
Study completion Jul 20, 2020
Sponsor
- Lead sponsor
- AO GENERIUMIndustry
- Sponsor type
- Industry
- First posted
- Jul 7, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
It is a multicenter, open-label, randomized, parallel-group study of the efficacy and safety of Tigerase® (GENERIUM JSC, Russia) with standard therapy versus standard therapy in patients with COVID-19.
Conditions
- COVID-19
- Coronavirus Disease 2019
Interventions
Tigerase® and best available careBiological
Nebulised dornase alfa \[2.5 mg BID\] for 7 days
Best available careOther
Patients will receive the usual care in accordance with good practice.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The proportion of patients with mechanical ventilationTime frame: Day 8
- Category change on WHO Ordinal Scale for Clinical ImprovementTime frame: Day 8
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
City Clinical Hospital #15
Moscow, Russia
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Moscow, Russia
City Clinical Hospital #51
Moscow, Russia
City Clinical Hospital #52
Moscow, Russia
N.V. Sklifosovsky Scientific Research Institute of First Aid
Moscow, Russia
Siberian State Medical University (SibMed)
Moscow, Russia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.